HAYA Therapeutics doses first cohort in Phase I HTX-001 trial

HAYA Therapeutics has announced full enrolment and dosing of the first cohort in its Phase I clinical trial of HTX-001. HAYA Therapeutics co-founder and CSO Daniel Blessing led HTX-001 research and development from concept to clinical trial. nHCM is characterised by thickening of the heart wall, left ventricular hypertrophy, impaired diastolic function and significant fibrosis. Credit: NMK-Studio / Shutterstock.com. HAYA Therapeutics has announced full enrolment and dosing of the first cohort in its Phase I clinical trial of HTX-001, a long non-coding ribonucleic acid (lncRNA)-targeting therapy developed for non-obstructive hypertrophic cardiomyopathy (nHCM). HTX-001 represents an approach aimed at modifying disease…

Source: Clinical Trials Arena